Insilico rises 2% on FDA fast track for mesothelioma drug ISM6331

Insilico Medicine received FDA Fast Track designation for ISM6331, a pan-TEAD inhibitor for advanced mesothelioma patients who progressed after two prior therapies. The designation accelerates development and review for the AI-designed drug targeting the Hippo signaling pathway.

"The Fast Track designation is intended to facilitate the development of new drugs for serious or life-threatening diseases and address unmet medical needs, while accelerating the review process," the company said.

The designation covers adult patients with unresectable malignant pleural mesothelioma whose disease progressed after anti-PD-1 antibody therapy (with or without anti-CTLA-4 treatment) and platinum-based chemotherapy. ISM6331 will now benefit from more frequent FDA meetings on trial design, biomarker strategies and development plans, and may qualify for accelerated approval, priority review and rolling review.

Insilico shares rose 2.1% to HKD43.80 on the Hong Kong Stock Exchange, with short selling accounting for 6.7% of turnover. HSBC Research initiated coverage with a Buy rating and HKD84.50 price target, implying roughly 93% upside. The company's Phase 1 data for ISM6331 was also accepted for a Rapid Oral presentation at the European Society for Medical Oncology Congress in Madrid from Oct. 23-27.

ISM6331 was discovered and designed using Insilico's proprietary generative AI platform, Chemistry42. The molecule targets TEAD transcription factors, the principal downstream effectors of the Hippo signaling pathway, which regulates cell proliferation, survival and therapeutic resistance across a broad range of solid tumors. Small-molecule inhibition of TEAD has historically posed significant design challenges, according to the company.

The Fast Track designation reduces regulatory risk for ISM6331 and opens pathways for accelerated approval in a patient population with limited therapeutic options. Patients with advanced mesothelioma and other Hippo-driven solid tumors currently face few effective treatments after standard therapies fail. The Phase 1 trial is evaluating ISM6331's safety, tolerability, pharmacokinetics and preliminary antitumor activity in a global, multicenter study. Investors will watch the data readout at ESMO in October for the first clinical glimpse of the molecule's profile.

This article is for informational purposes only and does not constitute investment advice.